Silexion Therapeutics Corp. (NASDAQ: SLXN) will present at the 27th Annual H.C. Wainwright Global Investment Conference on September 10, 2025, in New York City. The company is known for pioneering RNA interference therapies for KRAS-driven cancers. Silexion’s management team will be available for one-on-one investor meetings during the event. The company is dedicated to developing innovative treatments for solid tumor cancers with the mutated KRAS oncogene, focusing on advancing therapies for locally advanced pancreatic cancer. For more information, visit Silexion’s website or contact the company directly.

Read more at GlobeNewswire: Silexion Therapeutics to Present at the Upcoming 27th